secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001437749-24-013687
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics Q1 revenue $3.8M; net loss narrows; CMS Medicare reimbursement for Indego Personal
--------------------------------------------------------------------------------

- Revenue $3.8M (down 7% YoY from $4.1M); gross margin improved to 52% from 49%.
- Net loss narrowed to $3.4M ($0.20 per share) compared to $4.4M ($0.33) in Q1 2023.
- CMS issued final Medicare payment determination for Ekso Indego Personal, enabling reimbursement.
- Sold 29 EksoHealth units in Q1; cash and restricted cash $8.8M at March 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000143774924013687/0001437749-24-013687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000143774924013687/ekso20240425_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-013687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer